本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Highlights of Annual Results for the Year Ended December 31, 2024Revenue reached RMB1,986.7 millionGross profit amounted to RMB687.4 millionNet profit recorded RMB222.0 million, a significant turnaround from a year agoAdjusted Non-IFRS net profit recorded RMB314.6 million, a YOY increase of nearly 50.6%. SHANGHAI, March 27, 2025 /PRNewswire/ -- On March 27, 2025, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue during the Reporting Period achieved RMB1,986.7 million, gross profit amounted to RMB687.4 million and net profit recorded RMB222.0 million, a significant turnaround from a net loss of RMB99.8 million in the corresponding period of last year, mainly benefiting from the elimination of relevant financial adjustments due to the full repayment of convertible bonds, and an increase in adjusted non-IFRS net profit to RMB314.6 million from RMB208.8 million in the corresponding period of last year, representing an increase of nearly 50.6% as compared to last year, which was mainly attributable to an increase in operating profit margin driven by the recovery of CRO business growth and the improving operational efficiency in 2H2024, as well as the recognition of investment income from milestone payments received by the Group during the year. In addition, the Group's subsidiary Viva Biotech Shanghai was successfully restructured into a joint stock limited company on September 27, 2024, as the Group currently holds approximately 72.9% of its total issued share capital. During the Reporting Period, the Group's management and its strategic investors commenced a number of collaborations with full mutual trust, fully utilizing the strategic investors' strengths in global vision, capital markets and strategic resources to empower the Group's continuous enhancement in corporate governance, business operations, investment and financing as well as strategic planning. CRO Revenue Growth Improved Significantly Improving in the Second Half of the Year to Sustain a Recovery Momentum Ahead In 2024, the revenue of the Company's CRO business decreased by approximately 4.0% to RMB810.9 million from RMB844.9 million in the same period of last year, while the corresponding adjusted gross profit decreased by approximately 1.9% to RMB357.1 million from RMB363.8 million in the same period of last year. The decrease in CRO revenue in 2024 as compared to previous years was mainly attributable to the short-term impact of the global biopharmaceutical investment and financing pressure in 2023 on the R&D investment in innovative drugs in 1H2024. However, with the gradual recovery of global biopharmaceutical investment and financing since 2024, the Company's CRO revenue in 2H2024 has realized positive year-on-year and quarter-on-quarter growth compared with the same period last year and the first half of 2024. In addition, the CRO order value has realized positive growth year-on-year, and the monthly new order value is still maintained at a high level, which will drive the Company's CRO revenue to further maintain the rebound trend in 2025. Meanwhile, the Company has also taken a series of effective measures to enhance operational efficiency to maintain the profitability of CRO at a higher level. As of December 31, 2024, the Company's cumulative number of CRO customers increased to 1,568, including the world's top 10 pharmaceutical companies (based on the total revenue of the 2024 annual report), with the revenue share of the top 10 customers accounting for 24.4%. The CRO business has a diversified geographical distribution of customers, with the revenue share from overseas regions accounting for approximately 87.3%. Revenue from customers in Mainland China accounted for approximately 12.7%. As of the end of 2024, the Company has cumulatively delivered more than 82,716 protein structures to the clients, approximately 17,681 of which were newly delivered in 2024. The R&D of the Company has accumulated over 2,098 independent drug targets, 112 of which were newly delivered in 2024. Currently, the Company maintains a leading global position in the industry in the field of protein structure analysis. During the Reporting Period, the utilization of synchrotron radiation source reached 1,867 hours. The Company established long-term cooperation with 13 synchrotron radiation source centers around the world, the Company will ensure uninterrupted data collection throughout the year. In terms of marketing and business development, on one hand, the Company will obtain integrated service orders by fostering synergistic development of biological and chemical segments, on the other hand, the Company will actively continue to enhance the integration of digital marketing and offline business development (BD), while expanding its global BD team. During the Reporting Period, the Group not only strengthened its presence in the European market, but also established a branch in Boston, the United States. This marked a new milestone in the Company's global footprints, allowing us to further expand and deepen the international cooperation network. Moreover, the Company attaches great importance to the important role of artificial intelligence (AI) in drug R&D. Based on the efforts in improving efficiency and success rate, the Company combines dry and wet experiments to expand quantity and scale of new projects continuously. It is worth mentioning that by the end of 2024, the Company had participated in 157 AIDD projects, and the cumulative number of customers purchasing CADD/AIDD reached 51. Revenue from AI-enabled projects exceeded US$10 million, and cooperation with renowned institutions regarding a complete set of AI discovery solutions has been reached in some niche fields. New Commercial CDMO Projects to be Launched Soon and the CMC Business Optimization and Adjustment Largely Completed The Group is committed to building a one-stop service platform from R&D to production of global innovative drugs. Through the 100% equity interests acquisition of Zhejiang Langhua Pharmaceutical Co., Ltd (Langhua Pharmaceutical), the Group has been able to complete the deployment of the production side of the business. During the Reporting Period, the Group continued to expand CDMO capacity to prepare for commercial production of new molecules in the future. In addition, the Company completed optimization and adjustment of the CMC business. In 2024, Langhua Pharmaceutical recorded revenue of RMB1,175.7 million and the adjusted gross profit of RMB344.5 million. As of December 31, 2024, Langhua Pharmaceutical had served 897 clients, with 66.8% of revenue accounted for by the top ten customers and 100% retention rate of the top ten customers. Currently, Langhua Pharmaceutical's CDMO business, in addition to the existing commercialized projects that can maintain natural growth, has two important new commercialized projects that are at the process performance qualification (PPQ) stage and are expected to be commercially launched in 2025 and 2026, respectively, which will serve as a new growth driver for the CDMO business in the future. With respect to production capacity, the current total available total capacity has reached 860 cubic meters. In addition, Langhua Pharmaceutical plans to establish a new production capacity of 400 cubic meters between 2024 and 2025 to cater the commercial production of new molecules, and the civil construction work has already been completed. This endeavor will provide sufficient assurance for the Company's revenue growth with the launch of new products and release of reserved capacity in the future. Langhua Pharmaceutical will continue to adhere to the principles of customer first and regulatory compliance in quality management, strengthen cooperation with quality customers, and continuously improve and enhance the guidance and operability of the quality system. During the Reporting Period, Langham Pharmaceutical passed the on-site inspections of WHO and FDA again, which fully demonstrates that the quality system of Langham Pharmaceutical is further well aligned with the international system standards, and can guarantee the provision of quality, safe and reliable CDMO services to the world's leading pharmaceutical enterprises. In 2024, the Group adjusted its CMC business structure by focusing more on synthesis and analytics operations, strengthened BD efforts to overseas customers, and promoted continuous improvement in profitability through cost reduction, efficiency enhancement and customer mix optimization. Since its establishment, CMC has completed and is currently progressing with a total of 255 new drug projects, driven by a CMC R&D team of 105 members, and generated revenue of nearly RMB43.0 million. In addition, the projects channeled by the Group progressed smoothly, and one pipeline has rapidly advanced to Phase III clinical trials, showcasing the success of the Group's integrated strategy. In the future, the Group will further strengthen the BD and channeling efforts for acquiring high-quality CMC projects with a view to promoting revenue growth and profitability improvement of the CMC business on the basis of fully utilizing internal project resources, reducing costs and increasing efficiency. Partial Exits of Incubation Portfolio Companies Continued to Realize Investment Returns, Accretive to the Group's Profits During the Reporting Period, the Company achieved partial investment exits from a number of portfolio companies (Focus-X, Saverna, Dogma, Riparian, DTX and Nerio), realizing corresponding investment returns and generating total proceeds of nearly RMB162.5 million. As of December 31, 2024, the Group had invested in a total of 93 portfolio companies. The portfolio companies are mainly from the United States, Canada, Europe and China. 67.7% of the portfolio companies are from North America and 25.8% are from China. In 2024, 11 of the Company's portfolio companies completed or were close to completing a new round of financing, raising approximately US$292.7 million. The R&D efforts of the portfolio companies were advancing smoothly, with the total number of pipeline projects reaching close to 227, of which 186 pipelines are in the preclinical stage and 41 pipelines in the clinical stage. So far, the Group has successfully realized 15 investment exits or partial exits. Furthermore, the Group may have several potential exits of our portfolio companies, and it also can be foreseen that a peak season of investment exits will arrive in the next three years. As of December 31, 2024, the Company has strategically invested in a series of high-quality assets, including portfolio companies such as Haya, Mediar, Nerio, Full-Life, Absci, Dogma, Arthrosi, Basking, Cybrexa and FuseBio. In the future, as these portfolio companies to develop successfully, secure ongoing financing, and realize exits, the initial investments will gradually enter the harvesting phase, providing sustained cash returns and investment income for the Group. Technology Highlights and R&D Breakthroughs Viva Biotech's artificial intelligence technology, accumulated and developed over many years, is empowering its entire drug discovery platform. The current AI capabilities cover the full workflow of FIC drug discovery and are gradually transforming the logical paradigm of drug discovery through end-to-end integration. By focusing on new targets, novel MOA and new modalities, Viva Biotech has developed distinctive AI capabilities, driving its one-stop innovative drug R&D service platform from "AI-assisted" to "AI-driven". New Target A series of target protein structures not reported in the PDB protein structure database have been delivered to customers. Novel MOA Including allosteric mechanisms, target selectivity and conformational selectivity. Comprehensive drug discovery technologies such as DEL, ASMS, Intact-MS, SPR, NMR, crystal soaking, virtual screening, membrane protein technology, phage display and HTS; as well as various experimental validation techniques including protein crystal structures, Cryo-EM structures, HDX-MS and Bioassay. Additionally, the Company provides medicinal chemistry, computational chemistry, Pharmacology and DMPK services. New Modality Established platforms such as the XDC platform, peptide technology platform, PROTAC/molecular glue platform, and antibody/large molecule R&D technology platform. XDC Platform: Successfully integrated biologics/antibody platforms, peptide platforms, and small molecule drug platforms into the XDC large platform, covering multiple fields and capable of supporting various conjugated molecular models such as ADC, RDC, AOC, APC, DAC, etc. Additionally, the XDC platform has been deeply integrated with AIDD/CADD technologies and DEL technologies. Peptide Technology Platform: At the peptide discovery journey, a new AI-based peptide generation method has been developed, as well as a peptide screening strategy combining DEL/phage display screening data with AI analysis capabilities. Through a multi-dimension peptide research and development approach, the success rate of customer peptide R&D has been comprehensively improved. The company also provides one-stop peptide R&D and partial production services, including synthesis, biological testing, and PK research. PROTAC/ Molecular Glue Platform: PROTAC/molecular glue-related services account for approximately 10.75% of the CRO's total revenue. Over 50 E3 ligases have been researched, and more than 150 PROTAC ternary complexes have been delivered. Macromolecular Drug/Antibody Platform: By combining AIDD/CADD technologies, multiple high-difficulty antibody affinity modification projects and patent breakthroughs have been successfully completed. Furthermore, the antibody R&D platform has been enhanced through the expansion and improvement of bispecific antibody design platforms, high-throughput antibody rapid expression platforms, mRNA immunization, gene gun immunization, and other technologies. AI-enabled SBDD One-Stop Novel Drug R&D Service Platform The Company's AIDD and CADD platforms possess proprietary algorithms and platform-building capabilities, along with experience in developing various drug modalities. Leveraging Viva Biotech's strengths in structure-based drug R&D and supported by the computational power of the Shanghai supercomputing cluster, these platforms comprehensively empower all stages of early drug development. Building on this foundation, Viva Biotech is transitioning from a phase where computational methods primarily supported various drug development stages to a new phase where AI drives drug design, integrates with experimentation, and transforms the drug design paradigm. Staff and Facilities As at December 31, 2024, the Group had a total of 2,063 employees, of whom the number of CRO R&D personnel reached 1,121, and the headcount of Langhua Pharmaceutical was 711. The Company has well-established office and laboratory facilities in line, and is expanding production capacity to meet the fast-growing business needs, including: The Group's headquarters in Zhoupu, Shanghai, with a total area of approximately 40,000 square meters. The incubation center located in Faladi Road, Shanghai has an actual usable area of approximately 7,576 square meters, including 5,552 square meters of laboratory area. The park in Chengdu is approximately 64,564 square meters, of which 12,210 square meters of properties had been put into use as at December 31, 2024, including 10,800 square meters of laboratory area. A park in Suzhou is approximately 7,545 square meters, including nearly 5,305 square meters of laboratory area. A park in Jiaxing is approximately 6,362 square meters, including nearly 5,335 square meters of laboratory area. Shanghai Supercomputing Center has been officially put into operation in 2021. At present, it can support computer-aided drug discovery (CADD) computation, artificial intelligence in drug discovery (AIDD) related computation, and crystal structure and Cryo-EM (Micro-ED) computation. The factory of Langhua Pharmaceutical in Taizhou, Zhejiang is approximately 35,168 square meters, including the Taizhou R&D center with an area of approximately 2,500 square meters. The R&D center of Ningbo Nuobai has an area of approximately 1,300 square meters and the office building of Ningbo Nuobai has an area of approximately 1,500 square meters. Dr. Mao Chen Cheney, Chairman and Chief Executive Officer of Viva Biotech, said, "With unique advantages in structure-based drug R&D (SBDD), the Company will increase the cross-sell between biological and chemical businesses, continue to strengthen the construction of a one-stop drug R&D and manufacturing service platform, deepen the synergy between CRO and CDMO business, improve the capacity building for front-end services and drive business to back-end services to further enhance the business funnel effect. The Company is in an effort to establish an open eco-system for global biopharma innovators. " About Viva Biotech Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs. As of December 31, 2024, Viva Biotech had cumulatively provided drug R&D and manufacturing services to 2,465 biotech and pharmaceutical clients around the world. We have invested and incubated 93 biotech start-ups in total. In the future, the company will continue to strengthen its technological barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world.
截至2024年12月31日止年度業績亮點：收入達人民幣1,986.7百萬元毛利達人民幣687.4百萬元淨利潤爲人民幣222.0百萬元，同比大幅扭虧爲盈經調整後Non-IFRS淨利潤爲人民幣314.6百萬元 同比增長近50.6% 上海2025年3月27日 /美通社/ -- 2025年3月27日，維亞生物科技控股集團（1873.HK）公佈，截至2024年12月31日止12個月（報告期），集團實現收入人民幣1,986.7百萬元，實現毛利人民幣687.4百萬元，實現淨利潤人民幣222.0百萬元，相較於去年同期淨虧損人民幣99.8百萬元大幅扭虧爲盈，主要得益於因可轉債的全額償還而帶來相關財務調整項的消除；經調整非國際財務報告準則（Non-IFRS）淨利潤由去年同期人民幣208.8百萬元提升至人民幣314.6百萬元，較去年同期增長近50.6%，主要歸因於CRO業務於本年度下半年恢復增長、營運效率提升令經營利潤率提升以及本集團於本年度內收到里程碑付款確認投資收益。 此外，集團控股子公司維亞上海已於2024年9月27日成功改制爲股份有限公司，目前集團持有相當其全部已發行股本的約72.9%。報告期內，集團管理層和集團的戰略投資人以充分互信展開多項合作，充分發揮戰略投資人在全球視野、資本市場和戰略資源方面的優勢，賦能集團在公司治理、業務運營、投融資及戰略規劃方面的持續提升。 CRO收入增速下半年顯著改善，未來有望持續回暖 2024年，公司CRO業務收入由去年同期人民幣844.9百萬元下降至人民幣810.9百萬元，降幅約爲4.0%；對應經調整毛利由去年同期人民幣363.8百萬元下降至人民幣357.1百萬元，降幅約爲1.9%。2024年CRO的收入較往年有所下降，主要歸因於2023年全球生物醫藥投融資承壓對2024上半年創新藥研發投入所造成的短期影響。但隨著2024年以來全球生物醫藥投融資的逐步回升，公司2024下半年CRO收入相較於去年同期及2024上半年均已實現了同比、環比正增長。此外，目前CRO在手訂單金額已實現同比正增長，且每月新簽訂單金額仍維持在較高水平，這將推動公司CRO收入在2025年進一步保持回暖的趨勢。與此同時，公司亦通過一系列提升運營效率的有效舉措，將CRO的盈利水平維持在較高的水平上。 截至2024年12月31日，公司累計CRO客戶數量增加至1,568家，包括全球前十大製藥公司（根據2024年報總營收計），前十大客戶收入佔比24.4%。CRO業務客戶分佈地區多元化，來自海外地區收入佔比約達87.3%，來自中國內地客戶收入佔比約爲12.7%。 公司累計向客戶交付超過82,716例蛋白結構，其中2024年新增交付約17,681例蛋白結構。研究累計超過2,098個獨立藥物靶標，其中2024年新增交付112個。目前，公司在蛋白結構解析領域仍然保持全世界範圍內行業龍頭的地位。2024年，同步輻射光源使用情况達1,867小時，爲公司與全球13家同步輻射光源中心保持長期合作，可確保全年無間斷的收集數據。 在市場推廣和商業拓展方面，一方面，公司會通過生物、化學的協同發展以獲取一體化服務的訂單；另一方面，公司會不斷加强綫上數字營銷和綫下BD的充分融合，並同步推動全球BD團隊的擴張。報告期內，維亞集團不僅加强了對歐洲市場的佈局，同時成立了美國波士頓分公司。這標誌著公司全球化佈局邁入新的里程碑，同時也將進一步拓展和深化國際合作網絡。除此之外，公司亦重視AI對藥物研發的重要作用，立足於提升效率及成功率的基礎之上，通過乾濕實驗結合的方式，拉動新項目數量及規模的不斷增長。值得一提的是，截止2024年底，AIDD已累計參與項目數達157個，採購CADD/AIDD的累計客戶數爲51家，AI參與賦能的項目實現收入逾千萬美元，並已在某些細分領域達成整套AI發現解决方案的知名合作。 CDMO新商業化項目上市在即，CMC業務的優化與調整已基本完成 集團致力於打造全球創新藥從研發到生産一站式服務平台，通過實現對浙江朗華製藥有限公司（朗華製藥）的全資收購，以完善生産端的佈局。報告期內，一方面，不斷推進對CDMO的産能建設以爲未來商業化階段的新分子做準備；另一方面，完成了對CMC業務的優化與調整。 朗華製藥2024年全年收入總計人民幣1,175.7百萬元，經調整毛利總計人民幣344.5百萬元。截至2024年12月31日，朗華製藥累計服務客戶達897家，前十大客戶收入佔比66.8%，前十大客戶留存率100%。目前，朗華製藥CDMO業務除了現有商業化項目能保持自然增長以外，另有兩個重要的新商業化項目已處於工藝性能確認（PPQ）階段，預計分別在2025年、2026年將實現商業化上市，這將成爲未來CDMO業務新的增長驅動力。産能建設方面，目前可使用的總産能爲860立方米，且計劃於2024年至2025年之間新建400立方米的産能以服務於新分子的商業化生産。未來，隨著新産品的落地和儲備産能的釋放，這將爲公司收入的增長提供充足保障。朗華製藥在質量管理上繼續秉承客戶至上、法規符合性優先原則，加强與優質客戶的合作，不斷完善與提升質量體系的指導性和可操作性。報告期內，再次通過WHO和FDA的現場檢查，這充分說明朗華的質量體系進一步與國際體系標準的良好接軌，可以保障爲國際一流的醫藥企業提供優質、安全和可靠的CDMO服務。 此外，2024年集團亦對CMC業務進行了業務結構的調整，更爲聚焦合成與分析業務，不斷加强對海外客戶的BD，通過降本增效及客戶結構優化的方式以推動盈利水平的不斷提升。CMC從成立至今，已完成及正在推進的新藥項目數爲255個，研發人員數量達到105人，實現收入近人民幣43.0百萬元。集團導流的項目推進順利，已有一項管綫進入臨床三期且進展迅速，顯示集團一體化戰略的成功。未來，集團會進一步加强對高質量CMC項目的BD及導流，在充分挖潛內部項目資源及降本增效的基礎之上，以推動CMC業務收入的增長及盈利能力的改善。 多家孵化公司已實現部分退出，持續兌現投資收益以增厚集團利潤 報告期內，公司通過實現了對多家孵化公司（Focus-X、Saverna、Dogma、Riparian、DTX和Nerio）的部分退出，成功兌現了相應的投資收益，累計獲得近人民幣162.5百萬元回款。截至2024年12月31日，共累計投資孵化93家初創公司。投資孵化企業主要來自於美國、加拿大、歐洲以及中國，其中67.7%來自北美地區，25.8%來自中國。 2024年全年，公司已孵化的初創公司當中已有11家完成或者接近完成新一輪融資，融資總額約292.7百萬美元。各孵化公司研發進展順利，累計在研管綫總數近227條，其中186條管綫處於臨床前階段，41條管綫已經處於臨床階段。目前，孵化項目已有15家公司實現全部或部分退出。此外，還存在數個有潛在退出可能性的項目，預計在未來3年內將迎來退出高峰期。 截至2024年12月31日，維亞的投資孵化企業當中已佈局了例如：Haya、Mediar、Nerio、Full-Life、Absci、Dogma、Arthrosi、Basking、Cybrexa和FuseBio等一系列優質資産。未來，隨著孵化企業的順利發展、持續融資及退出，前期的投資將逐漸進入收穫期並爲集團持續帶來現金回報及投資收益。 技術亮點及研發突破 維亞經過多年積累和發展的人工智能技術正在賦能整個藥物發現平台，目前的AI能力已經覆蓋FIC藥物發現的全工作流程，並通過端到端的能力整合逐步改變藥物發現的邏輯範式，圍繞新靶點（New Target）、新機理（Novel MOA）及新藥物類型（New Modality）開發出維亞獨具特色AI能力，推動公司的一站式原創新藥物研發服務平台從「AI輔助」向「AI驅動」發展。 新靶點研究 已向客戶交付了一系列在PDB蛋白結構數據庫未有報道的靶標蛋白結構。 新機理研究 包括變構機理、靶點選擇性、構象選擇性。綜合性藥物發現技術如DEL、ASMS、Intact-MS、SPR、NMR、晶體浸泡、虛擬篩選、膜蛋白技術、噬菌體展示、HTS等；各種實驗驗證技術如蛋白質晶體結構、冷凍電鏡結構、HDX-MS、Bioassay等。公司亦能提供藥物化學、計算化學及藥理學和藥物代謝服務。 新藥物類型 已搭建XDC大平台、多肽技術平台、PROTAC/分子膠、抗體/大分子研發技術平台等。 XDC大平台：已成功將大分子藥物/抗體平台、多肽平台及小分子藥物平台整合成覆蓋多領域的XDC大平台，能覆蓋不同的偶聯分子模式如：ADC、RDC、AOC、APC、DAC等。並且，已實現了XDC技術與AIDD/CADD技術、DEL技術的深度融合。 多肽技術平台：在多肽發現端，開發了基於AI的全新多肽生成方法以及將DEL/噬菌體展示篩選數據與AI分析能力結合的多肽篩選策略，通過多角度的多肽研發技術，綜合提高客戶多肽研發的成功率。同時，公司也能够提供各種多肽的合成、生物檢測及PK研究等一站式多肽研發及部分生産服務。 PROTAC/分子膠研發技術平台：PROTAC/分子膠相關服務約佔CRO總收入的10.75%，已累計研究E3連接酶50多個，交付PROTAC三元複合物150多個。 抗體/大分子研發技術平台：結合AIDD/CADD技術，成功完成了多個高難度抗體親和力改造項目和專利突破項目。此外，通過拓展和改進雙特異抗體設計平台、高通量抗體快速表達平台、mRNA免疫、基因槍免疫等技術進一步完善了抗體研發平台。 AI賦能SBDD一站式原創新藥物研發服務平台 公司AIDD及CADD平台具備自研算法及平台建設的能力、擁有研發多種藥物形態的經驗、並且充分發揮了維亞基於結構的藥物研發優勢，在上海超算集群的算力支持下，能够對早期藥物研發的各個環節進行全面賦能。在此基礎之上，維亞正在從以計算方法爲各個藥物研發階段賦能爲主的階段邁向以AI驅動藥物設計，改變藥物設計範式的新階段。 人員及設施 截至2024年12月31日，本集團員工總人數爲2,063人，CRO研發人員數量達到1,121人，朗華製藥總人數爲711人。公司已經建設了完善的辦公和實驗場地，産能擴張以滿足公司高速發展的業務需求，包括： 上海周浦集團總部，總面積約40,000平方米。 上海法拉第路投資孵化中心實際可使用面積約7,576平方米，其中包含實驗室面積5,552平方米。 成都園區的建築面積約爲64,564平方米，截至2024年12月31日，已有12,210平方米物業部分正式投入使用，其中包含實驗室面積10,800平方米。 蘇州園區總建築面積約爲7,545平方米，其中實驗室面積近5,305平方米。 嘉興園區建築面積約爲6,362平方米，其中實驗室面積近5,335平方米。 上海超算中心已於2021年投入使用，目前能够支持計算化學（CADD）計算、人工智能（AIDD）相關計算以及晶體組和冷凍電鏡組的運算等。 浙江台州工廠的建築面積約爲35,168平方米，台州研發中心面積約爲2,500平方米。寧波研發中心面積約爲1,300平方米，寧波辦公樓面積約爲1,500平方米。 維亞生物主席兼首席執行官毛晨博士：「公司憑藉在基於結構的藥物研發（SBDD）領域的獨特優勢，提升生物和化學業務之間的導流效應，持續加强一站式原創新藥物研發平台和生産服務平台的建設，深化CRO與CDMO業務間的協同性，提升前端項目業務能力建設，促使漏斗效應進一步顯現，加速爲後端業務導流，積極構建面向全球生物醫藥創新者的開放式合作平台和共贏生態圈。」 關於維亞生物 維亞生物（01873. HK）成立於2008年，向全球創新藥研發企業提供從早期基於結構的藥物研發到商業化藥物生産的一站式綜合服務。憑藉在基於結構的藥物研發（SBDD）技術領域的領先優勢，我們向全球合作夥伴提供新藥研究階段的CRO服務，搭建了X射綫蛋白晶體技術、冷凍電鏡技術（Cryo-EM）、DNA編碼化合物庫技術（DEL）、親和力質譜篩選技術（ASMS）、表面等離子共振技術（SPR）、氫氘交換質譜技術（HDX-MS）、AIDD/CADD等多個先進技術平台，並有資深藥物化學家與藥物發現生物專家領軍的團隊提供藥物設計、藥物化學（H2L，LO）、化合物合成、化學分析及純化、公斤級放大及多肽合成及相應的生物活性測試服務。通過子公司朗華製藥，我們提供從臨床前開發到商業化生産的一站式CMC/CDMO解决方案。同時，我們專注於發現、投資高潛力生物醫藥初創公司，以獨創的技術服務換取股權（EFS）的商業模式，解决未滿足的臨床需求。 截至2024年12月31日，維亞生物已累計爲全球2,465家生物科技及製藥客戶提供藥物研發及生産服務，共計投資孵化93家生物醫藥初創企業。未來，公司將持續增强技術壁壘、提升研發與生産服務能力，爲全球更多的初創新藥公司及中大型藥企提供優質的多元化服務，助益全球病患。
【2025年3月27日，台北訊】外貿協會今日宣布聯發科技執行長蔡力行博士將以「從邊緣AI到雲端AI的願景」為題，在COMPUTEX 2025發表主題演講，該演講將於展覽開幕第一天5月20日上午11:00（UTC+8）於台北南港展覽館2館7樓舉行，歡迎業者踴躍參與。 作為全球半導體技術與AI運算的領導者，聯發科技持續在各式裝置、智慧家庭、車用電子、物聯網，以及資料中心等推動創新。聯發科技執行長蔡力行博士將在COMPUTEX 2025分享聯發科技從邊緣AI到雲端AI運算領域的願景，探討次世代通訊技術的革新，以及如何透過高效能、高能效晶片形塑智慧裝置的未來。 蔡博士在半導體和科技產業擁有豐富的領導經驗。在他的領導下，聯發科技進一步強化先進晶片的創新，並推動各類技術平台的發展。蔡博士的演講主題將深入探討AI、6G、邊緣運算、雲端運算在數位轉型所扮演的角色，並展現聯發科技如何將無所不在的智慧融合運算帶到所有人身邊的企業願景。 COMPUTEX 2025以「AI Next」為主軸，將於5月20日至5月23日於台北南港展覽館1、2館登場，吸引近1,400家廠商，聚焦「智慧運算&機器人」、「次世代科技」及「未來移動」三大主題，歡迎有興趣人士一睹全球科技風采。COMPUTEX Keynote將於4月開放報名，最新活動資訊請至官網www.computextaipei.com.tw查詢。 更多展覽相關訊息，請自以下官網查詢： COMPUTEX官網：www.computextaipei.com.tw InnoVEX官網：www.innovex.com.tw 關於COMPUTEX COMPUTEX創辦於1981年，40年來一路與全球ICT產業一同成長、茁壯，見證產業發展與轉變的歷史性時刻，每年吸引超過4萬名的國際買主來台參觀及採購，亦是國際指標廠商選擇公布劃時代產品的首選平台。 台灣具備完整全球資通訊產業鏈，立足台灣的COMPUTEX，為中華民國對外貿易發展協會與台北市電腦商業同業公會共同主辦，以建構全球科技生態系為目標，期望以跨領域整合創新服務作為最強勁的動力，成為全球科技資源整合的新舞台。 關於外貿協會 中華民國對外貿易發展協會（簡稱外貿協會或貿協）為台灣最重要的貿易推廣機構，係由經濟部結合民間工商團體成立之公益性財團法人，以協助業者拓展對外貿易為設立宗旨。目前，本會擁有1,300多位海內外專業經貿人員，除台北總部外，設有桃園、新竹、台中、台南及高雄等5個國內辦事處、遍佈全球各地超過60個海外據點及超過300個簽有合作協議之國際貿易推廣姐妹機構，形成完整的貿易服務網，提供零時差、無國界的即時服務，持續與廠商共同追求台灣經濟的穩健發展，是業者拓展貿易的最佳夥伴。 2020年，甫迎50週年的外貿協會，為強化跨領域整合創新，本會重新定位為國際鏈結智慧整合中心（smart integrator），結合法人、大學、觀光、展會、城市、公協會、海外台商，為業者開發國際市場、進行國際合作、數位轉型、連接國際網絡，提供整合性、數位化服務，期許成為台灣「數位經貿的領航者」及「創新模式的推動者」。
2025 洛克威爾自動化大學開課，探索高效、安全、永續生產新解方 【台北訊，2025 年 3 月 27 日】全球工業自動化與數位轉型領導品牌洛克威爾自動化今（27）日舉辦「2025 洛克威爾自動化大學」研討會，由洛克威爾自動化亞太區總裁 Scott Wooldridge 帶領，以「AI 創新顛覆傳統製造」為題深入剖析全球產業趨勢，並匯集各領域的專家與合作夥伴，憑藉豐富的實戰經驗，共同探討 AI 時代下的製程優化及數位創新技術，攜手台灣產業率先布局工業自主化未來。 洛克威爾自動化亞太區總裁 Scott Wooldridge 表示：「AI 創新顛覆了傳統製造業的成長模式，當 AI 技術整合至現有工作流程中，深度應用於控制層並建立自主學習的環境，工業自動化將邁向自主化的未來。同時，機器人與軟體定義自動化將為製造產業提升創造力、生產力和價值，開啟全新的想像。」 洛克威爾自動化台灣區總經理譚世宏表示：「台灣產業普遍面臨人才不足、淨零轉型與全球供應鏈重組等問題，傳統製造業升級設備的需求殷切，以加速推進轉型進程，期望藉由洛克威爾自動化大學與在地企業深入交流，實現數位賦能和提升競爭力。」 2025 洛克威爾自動化大學齊聚智慧製造專家，三大主題全面展示多元解決方案如何助攻數位轉型： l 精準製程管理提升生產效能：數位基礎是邁向智慧化與自主化的首要目標，而洛克威爾自動化於變頻器、感測器、控制元件等組件層面即內建聯網功能，借助高相容性、模組化等特性，協助企業從關鍵硬體中部署數位功能，加速轉型基礎建置。近期，洛克威爾自動化與 NVIDIA 展開戰略合作，以數位分身技術打造物理仿真模擬工廠，實現工廠級別的虛擬控制測試，並幫助企業於部署前進行驗證，降低產線擴張或調整時的風險。 l 數據驅動強化營運與資安：在數位基礎建立後，前線人員採用 FactoryTalk Optix 人機介面，一站式收集、整合、可視化數據，並串接第三方應用程式實現深度分析，轉化洞察為行動；Plex 製造執行系統 SaaS（軟體即服務）則提供雲端原生的機台管理與製程追蹤，產線可更緊密地連結設備與供應鏈。當 OT 與 IT 連結程度提升，不能忽視建立安全的數位防線，洛克威爾自動化強調以 OT 資安解決方案強化架構，同時建立 OT／IT 端人員的資安意識，強化企業風險管理能力。 l AI 創新推動高質量智造：AI 與邊緣運算協助產線進行維護，提供潛在故障風險及維修週期洞察，大幅降低潛在停機時間。同時，將 AI 導入至實際製程中，FactoryTalk Analytics VisionAI 以視覺 AI 進行品質管理，提升機器視覺於品質判別的準確率及效率。 前瞻技術和顧問輔導加值轉型量能，引領台灣產業持續升級 洛克威爾自動化長期推動產業升級，透過全球 OEM 技術顧問（GOTC）和 PartnerNetwork 服務，見證許多台灣企業邁向新工業模式，包含： l 智慧系統整合領導商廣運機械將 Emulate3D 數位分身技術應用於物流系統，在虛擬環境中的物流模擬、機械設計及產能驗證，優化建置成本及作業效率，高度的物理仿真並降低虛實差異，減少實際部署的落差。 l 包裝機領導品牌虹興機械導入 iTRAK 智慧追蹤系統、Optix 數據平台等軟硬體，建置智慧彈性間距橫式包裝機，扭轉傳統機型維護成本高昂、缺乏標準化數據、無法及時監測生產等痛點。 關於洛克威爾自動化 洛克威爾自動化公司（NYSE:ROK）為工業自動化與數位轉型的全球領導品牌。結合想像力和科技的潛力，開創人類無限可能，打造高生產力與加倍永續化的世界。洛克威爾自動化總部位於美國威斯康辛州密爾瓦基市，旗下約有 27,000 名員工，致力服務遍布超過 100 國的客戶（統計截至 2024 財年）。如欲暸解更多我們如何在各工業企業中實現企業聯網（The Connected Enterprise）的相關資訊，請造訪 www.rockwellautomation.com/zh-tw.html。
New capital will support ongoing product innovation for the authentication and verification of digital content as the market continues to expand SAN MATEO, Calif., March 27, 2025 /PRNewswire/ -- GetReal Security, a cybersecurity leader specializing in the detection and mitigation of malicious generative AI threats including deepfakes and impersonation attacks, announced it has closed $17.5M in Series A funding led by global early-stage cybersecurity and AI investment firm Forgepoint Capital with participation from Ballistic Ventures, Evolution Equity, and K2 Access Fund as well as strategic investors In-Q-Tel (IQT), Cisco Investments and Capital One Ventures. Joining the company's board of directors are Forgepoint Capital Co-Founder and Managing Director Alberto Yépez and GetReal Co-Founder and Chief Science Officer Dr. Hany Farid, the preeminent digital forensics expert in the field. This new capital will fuel GetReal's R&D, product development, and go-to-market operations as the company addresses the rapidly evolving threat environment associated with generative AI and digital content. "Developments in foundation models and generative AI have evolved the attack surface well beyond traditional networks and infrastructures, opening up new vulnerabilities in protecting the modern digital enterprise. This means that the verification and authentication of digital content – whether text, images, audio, or video – is a critical new frontier of enterprise risk management as organizations have become prime targets for manipulation and exploitation," said Yépez. "What sets the GetReal team apart is their combination of world-class digital forensics and deep cyber domain expertise. The team is uniquely positioned to address this challenge and equip enterprises to defend against this new attack vector." The proliferation and general adoption of AI have introduced both opportunities and challenges for enterprises, including the ease with which AI-generated content can be used for both legitimate and illegitimate purposes. The result is a new attack technique that targets any organization relying on digital communications to run their business – virtually every business today – undermining trust in critical information and challenging their ability to make effective business decisions. Attackers are already successfully deploying manipulated digital content to deceive employees into sharing sensitive data, executives into authorizing fraudulent transactions, and customers into trusting falsified communication. "We've reached a pivotal moment. AI-generated content is on the verge of dominating the digital landscape and bad actors are already exploiting these advancements," said Ted Schlein, Chairman and Co-Founder of GetReal and Co-Founder and General Partner of Ballistic Ventures. "The need for solutions that can quickly and accurately verify and authenticate digital media has never been more critical. We're happy to welcome these new investors to our syndicate, and we look forward to working together to protect enterprises and governments from the growing threats posed by AI-driven deception." GetReal offers a complete set of solutions designed to help organizations effectively manage risk and mitigate threats from these new types of AI-fueled attacks. All products and services are offered through GetReal's unified platform which provides the infrastructure to accommodate all modalities (image, audio and video) for both files and real-time digital communication streams. The company also offers enterprise-class services to help organizations train security teams, develop policy, and deploy solutions. Its newly launched incident response service, GetReal Respond, was designed to help organizations deal with complex incidents requiring the highest level of forensic analysis, and leverages GetReal's team of digital forensics experts and investigators for advanced analysis. "As we've seen so many times before in the cybersecurity industry, when sophisticated tools become easily accessible, adversaries will strike. This time will be no different," said Matt Moynahan, CEO of GetReal. "When people can't trust what they see, hear, or read, it will challenge every organization's ability to execute. GetReal's mission is to tackle this challenge head-on, and I'm proud to be working alongside this talented team to combat it." "I'm heartened that these quality investors understand the profound implications that unchecked malicious generative AI can have on the greater good and are joining our cause to build GetReal into a transformative cybersecurity company," said Farid. "I've dedicated my career to advancing digital forensics techniques and advising on cases where manipulated content has dire real-world consequences. Our solution set is a significant step forward in our mission to create best-in-class content verification and authentication capabilities to navigate an era where synthetic content is increasingly indistinguishable from reality." To learn more about GetReal and what's ahead, read Moynahan's blog here and visit www.getrealsecurity.com About GetReal SecurityGetReal Security is the cybersecurity leader specializing in the detection and mitigation of threats posed by malicious generative AI content including deepfakes and impersonation attacks. Its technology serves multinational corporations, financial institutions, media organizations, government agencies, and social media companies. The company was incubated by Ballistic Ventures, the venture capital firm dedicated exclusively to funding and incubating entrepreneurs and innovations in cybersecurity, and Dr. Hany Farid, the preeminent expert in media forensics. Learn more at getrealsecurity.com and follow the company on LinkedIn. About Forgepoint CapitalForgepoint Capital is a leading venture capital firm that invests in transformative cybersecurity, artificial intelligence, and infrastructure software companies protecting the digital future. With over $1 billion in AUM, the largest sector-focused investment team, and portfolio of more than 30 companies, the firm brings over 100 years of proven company-building experience and its Advisory Council of more than 100 industry leaders to support entrepreneurs advancing innovation globally. Founded in 2015 and headquartered in the San Francisco Bay Area and London, Forgepoint is proud to help category-defining companies reach their market potential. Learn more at www.forgepointcap.com and on LinkedIn. Media Contactgetrealsecurity@inkhouse.com
Unified platform offers solutions and services to help effectively manage risk and mitigate attacks from new types of AI-fueled attacks SAN MATEO, Calif., March 27, 2025 /PRNewswire/ -- GetReal Security, the cybersecurity leader specializing in the detection and mitigation of malicious generative AI threats, including deepfakes and impersonation attacks, announced the launch of its unified platform to help enterprises, government agencies and media organizations manage risk and mitigate threats from the growing presence of AI-fueled attacks. The platform brings together GetReal's products and service offerings into a unified digital experience for users, providing the infrastructure to accommodate all modalities (image, audio and video) for both files and real-time digital communication streams. "The threat of deepfakes and manipulated media is more than one expert can handle alone. That's why we developed our suite of leading digital forensic and cybersecurity solutions and services to protect enterprises, governments, and media," said Dr. Hany Farid, Co-Founder of and Chief Science Officer at GetReal. "By developing a suite of digital forensic and cybersecurity capabilities that asynchronously and synchronously analyze images, audio, and video, we are empowering organizations across industries to figure out what's real and what's not and restore confidence in times of critical decision-making." As enterprises, governments and media organizations increasingly rely on images, audio, and video for critical decision making, there is a vested interest in ensuring the information they act on is accurate. This requires a shift in focus to the presentation layer of digital content—spanning images, audio, and video—to verify and authenticate what is real and what is fake. Legacy tools and traditional security trainings fail to address these multi-modal AI-generated threats accurately and in real-time. GetReal's platform provides a comprehensive approach to verifying the authenticity of digital communications helping to detect deepfakes, reduce risk, and prevent data compromise and fraud. By verifying and authenticating content, the platform empowers customers to confidently use images, audio, and video in business-critical decisions. "Protecting the modern digital enterprise demands a more holistic approach—one that goes beyond traditional tools and considers the full spectrum of malicious digital media and AI-driven threats. Enterprises, governments, and media organizations need to trust the digital content they rely on, both inside and outside their networks," said Jim Brennan, Chief Product & Technology Officer at GetReal. "Our platform brings everything together, providing a unified solution that authenticates images, audio, and video in real-time. With advanced forensics analysis and expert on-demand assistance, we're equipping enterprises with the capabilities they need to detect deepfakes, mitigate risk, and make critical decisions with confidence." GetReal's platform integrates its services and products into a single, cohesive platform for its users. Featuring a web-based UI, API access, and third-party integrations, it automates media analysis using AI, statistical methods, and digital forensics. Services and solutions include: GetReal Prepare provides organizations with a holistic view of current threat exposure through its readiness assessment. GetReal's cybersecurity veterans work with executive leadership to formulate an organization-wide action plan that includes policy development and awareness training for the organization. GetReal Inspect empowers organizations to safeguard their executives, employees and their brand with automated, on-demand forensic analysis to authenticate and verify audio, video, voice and image files. GetReal Protect delivers real-time analysis and alerts of audio and video streams to prevent bad actors at the onset before they can infiltrate an organization and cause further damage. GetReal Respond helps organizations deal with complex incidents requiring the highest level of forensic analysis, and leverages GetReal's team of digital forensics experts and investigators for advanced analysis. In addition to the debut of its new cloud-native platform, GetReal announced its $17.5M Series A today to further invest in R&D, product development and go-to-marketing operations. To learn more about GetReal's unified platform and product offerings, visit getrealsecurity.com. About GetReal SecurityGetReal Security is the cybersecurity leader specializing in the detection and mitigation of threats posed by malicious generative AI content including deepfakes and impersonation attacks. Its technology serves multinational corporations, financial institutions, media organizations, government agencies, and social media companies. The company was incubated by Ballistic Ventures, the venture capital firm dedicated exclusively to funding and incubating entrepreneurs and innovations in cybersecurity, and Dr. Hany Farid, the preeminent expert in media forensics. Learn more at www.getrealsecurity.com and follow the company on LinkedIn. Media Contactgetrealsecurity@inkhouse.com
AI
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
